bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'thanks', 'rectal', 'colorectal', 'beva']
we start with the plenary session. thanks, md. takayuki yoshino for sharing the result of the study with us. " panitumumab plus mfolfox6 versus bevacizumab plus mfolfox6 as first-line treatment in patients with ras wild-type metastatic colorectal cancer . 
Soy Internista y Oncólogo en la ciudad de Puebla. El tratamiento del cáncer debe de ser personalizado y adaptarse a las necesidades individuales del paciente.